557 related articles for article (PubMed ID: 7536072)
21. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
22. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
[TBL] [Abstract][Full Text] [Related]
23. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.
Jansen J; Thompson EM; Hanks S; Greenspan AR; Thompson JM; Dugan MJ; Akard LP
Bone Marrow Transplant; 1999 Jun; 23(12):1251-6. PubMed ID: 10414911
[TBL] [Abstract][Full Text] [Related]
25. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
[TBL] [Abstract][Full Text] [Related]
26. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D
Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
[TBL] [Abstract][Full Text] [Related]
27. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
[TBL] [Abstract][Full Text] [Related]
28. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.
Zimmerman TM; Mick R; Myers S; Bender JG; Lee WJ; Williams SF
Bone Marrow Transplant; 1995 Jun; 15(6):923-7. PubMed ID: 7581092
[TBL] [Abstract][Full Text] [Related]
29. High dose therapy and autologous bone marrow versus blood cell rescue. South Island Bone Marrow Transplant Unit.
Hill GR; Inder A; Patton WN; Hart DN
N Z Med J; 1996 Feb; 109(1016):45-8. PubMed ID: 8598936
[TBL] [Abstract][Full Text] [Related]
30. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor.
Kohno A; Takeyama K; Narabayashi M; Okamoto R; Adachi I; Tobinai K; Shimoyama M
Bone Marrow Transplant; 1995 Jan; 15(1):49-54. PubMed ID: 7538002
[TBL] [Abstract][Full Text] [Related]
31. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
Faucher C; Le Corroller AG; Chabannon C; Novakovitch G; Manonni P; Moatti JP; Nouyrigat P; Maraninchi D; Blaise D
Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350
[TBL] [Abstract][Full Text] [Related]
32. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
[TBL] [Abstract][Full Text] [Related]
34. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
36. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
[TBL] [Abstract][Full Text] [Related]
37. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia.
Andrews RG; Briddell RA; Hill R; Gough M; McNiece IK
Stem Cells; 1999; 17(4):210-8. PubMed ID: 10437984
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
39. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
Sawada H; Wake A; Yamasaki Y; Izumi Y
Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
[TBL] [Abstract][Full Text] [Related]
40. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]